Platelet factor 4 (PF4) displaced from endothelial cells, or directly from the platelets, binds to heparin molecule to form an immunogenic complex. heparin treatment, in patients with ET carrying V617F mutation, as compared with patients without mutations (P=0.029). ET with V617F mutation seems to be associated with higher risk of thrombotic complications during heparin treatment. […]